Harvard Bioscience Lifts Full-Year Outlook as Q2 Revenue Climbs 11%
HBIO sits 63% above its 52-week low of $3.755.
Summary
Harvard Bioscience reported Q2 2026 revenue of $22.7M, up 11% YoY, and raised full-year revenue guidance. Net loss narrowed slightly, but high debt costs and cash burn persist.
Key Events · Earnings and Guidance · HBIO
-
Q2 Revenue Beats, Guidance Raised
Revenue of $22.7M grew 11% YoY, driven by CRO and Asia Pacific demand. Full-year revenue guidance was raised, signaling confidence in the recovery.
-
Net Loss Narrows
Q2 net loss was $2.9M ($0.64/share) vs. $2.3M loss a year ago. The improvement reflects higher sales and lower amortization, partially offset by higher interest expense.
-
Cash Burn Continues
Cash fell to $6.5M from $8.6M at year-end. Operating cash flow was negative $0.3M for the first half, with inventory build and restructuring costs weighing.
-
Debt Costs Remain High
Total debt stands at $36.7M with an effective interest rate of 17.9%. Interest expense jumped 79% YoY to $1.8M in Q2, consuming a significant portion of gross profit.
Analysis · HBIO · Industrial Applications And Services
Harvard Bioscience posted Q2 revenue of $22.7 million, an 11% year-over-year gain, and raised its full-year revenue forecast. Cash burn remains a concern, with only $6.5 million on hand against $36.7 million in debt that carries a steep 17.9% effective interest rate. The Project Viking restructuring is proceeding as planned, though it added $0.3 million in charges this quarter. While the raised guidance points to strengthening demand, the balance sheet continues to look strained.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.5% of the 1476 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HBIO was trading at $6.13 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $27.6M. The 52-week trading range was $3.76 to $9.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.